Literature DB >> 29341398

What are the outcomes of declining a public health service increased risk liver donor for patients on the liver transplant waiting list?

Kristopher P Croome1, David D Lee1, Surakit Pungpapong1, Andrew P Keaveny1, C Burcin Taner1.   

Abstract

The tragedy of the national opioid epidemic has resulted in a significant increase in the number of opioid-related deaths and accordingly an increase in the number of potential donors designated Public Health Service (PHS) increased risk. Previous studies have demonstrated reluctance to use these PHS organs, and as a result, higher discard rates for these organs have been observed. All patients listed for liver transplantation in the United States from January 2005 to December 2016 were investigated. Patients on the waiting list were divided into 2 groups: those in which a PHS liver was used for transplantation (accepted PHS group) and those in which a PHS liver was declined and transplanted into a recipient lower on the match run (declined PHS group). Intention-to-treat patient survival from the time of PHS offer was significantly higher in the accepted PHS compared with the declined PHS group (P < 0.001). On Cox multivariate regression, declining a PHS donor liver was associated with a hazard ratio of 2.36 (95% confidence interval, 2.23-2.49; P < 0.001). For patients in which a PHS organ offer was declined, 11.6% died or were delisted for being too sick within the subsequent year. Donor liver allografts implanted in the accepted PHS group were of a lower donor risk index (1.28 versus 1.44) compared with the non-PHS organs that patients in the declined PHS group ultimately received if they underwent transplantation. In conclusion, there is a significantly higher survival for patients in which a PHS liver is accepted and used compared with those patients in which a PHS organ is declined. These data will help inform decisions about whether or not to accept a PHS donor liver for both patients and transplant professionals. Liver Transplantation 24 497-504 2018 AASLD.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2018        PMID: 29341398     DOI: 10.1002/lt.25009

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  10 in total

1.  Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients.

Authors:  Peng-Sheng Ting; James Peter Hamilton; Ahmet Gurakar; Nathalie H Urrunaga; Michelle Ma; Jaime Glorioso; Elizabeth King; Lindsey P Toman; Russell Wesson; Jacqueline Garonzik-Wang; Shane Ottmann; Benjamin Philosophe; Mark Sulkowski; Andrew M Cameron; Christine M Durand; Po-Hung Chen
Journal:  Transpl Infect Dis       Date:  2019-10-30       Impact factor: 2.228

2.  Quantifying the risk of undetected HIV, hepatitis B virus, or hepatitis C virus infection in Public Health Service increased risk donors.

Authors:  Jefferson M Jones; Brian M Gurbaxani; Alice Asher; Stephanie Sansom; Pallavi Annambhotla; Anne C Moorman; Saleem Kamili; John T Brooks; Sridhar V Basavaraju
Journal:  Am J Transplant       Date:  2019-05-10       Impact factor: 8.086

3.  Impact of US Public Health Service increased risk deceased donor designation on organ utilization.

Authors:  Mathew R P Sapiano; Jefferson M Jones; James Bowman; Marilyn E Levi; Sridhar V Basavaraju
Journal:  Am J Transplant       Date:  2019-05-03       Impact factor: 8.086

Review 4.  Increased-risk donors and solid organ transplantation: current practices and opportunities for improvement.

Authors:  Craig S Brown; Glenn K Wakam; Michael J Englesbe
Journal:  Curr Opin Organ Transplant       Date:  2020-04       Impact factor: 2.269

5.  Prevalence of Blood-Borne Viruses and Predictors of Risk in Potential Organ Donors in Australia.

Authors:  Martin J Dutch; Cameron J Patrick; Peter A Boan; Jonathan C Knott; Helen I Opdam
Journal:  Transpl Int       Date:  2022-05-03       Impact factor: 3.842

6.  Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014-2017.

Authors:  Danae Bixler; Pallavi Annambholta; Winston E Abara; Melissa G Collier; Jefferson Jones; Tonya Mixson-Hayden; Sridhar V Basavaraju; Sumathi Ramachandran; Saleem Kamili; Anne Moorman
Journal:  Am J Transplant       Date:  2019-04-29       Impact factor: 9.369

7.  Consent to organ offers from public health service "Increased Risk" donors decreases time to transplant and waitlist mortality.

Authors:  Yvonne M Kelly; Arya Zarinsefat; Mehdi Tavakol; Amy M Shui; Chiung-Yu Huang; John P Roberts
Journal:  BMC Med Ethics       Date:  2022-03-05       Impact factor: 2.652

8.  Donor quality of life after living donor liver transplantation: a review of the literature.

Authors:  Avesh J Thuluvath; John Peipert; Rachel Berkowitz; Osama Siddiqui; Bridget Whitehead; Arielle Thomas; Josh Levitsky; Juan Caicedo-Ramirez; Daniela P Ladner
Journal:  Dig Med Res       Date:  2021-09-30

Review 9.  Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?

Authors:  Paulina Czarnecka; Kinga Czarnecka; Olga Tronina; Teresa Baczkowska; Magdalena Durlik
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

10.  Using machine learning to estimate survival curves for patients receiving an increased risk for disease transmission heart, liver, or lung versus waiting for a standard organ.

Authors:  Ethan Mark; David Goldsman; Pinar Keskinocak; Joel Sokol
Journal:  Transpl Infect Dis       Date:  2019-10-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.